Cumberland Pharmaceuticals (CPIX) Competitors $1.06 -0.02 (-1.85%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CPIX vs. REPH, LLY, JNJ, ABBV, MRK, PFE, BMY, ZTS, RPRX, and JAZZShould you be buying Cumberland Pharmaceuticals stock or one of its competitors? The main competitors of Cumberland Pharmaceuticals include Recro Pharma (REPH), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), and Jazz Pharmaceuticals (JAZZ). Cumberland Pharmaceuticals vs. Recro Pharma Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol-Myers Squibb Zoetis Royalty Pharma Jazz Pharmaceuticals Recro Pharma (NASDAQ:REPH) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, dividends, profitability, earnings, media sentiment, valuation and risk. Does the MarketBeat Community prefer REPH or CPIX? Recro Pharma received 162 more outperform votes than Cumberland Pharmaceuticals when rated by MarketBeat users. Likewise, 54.28% of users gave Recro Pharma an outperform vote while only 42.60% of users gave Cumberland Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRecro PharmaOutperform Votes34954.28% Underperform Votes29445.72% Cumberland PharmaceuticalsOutperform Votes18742.60% Underperform Votes25257.40% Do insiders & institutionals have more ownership in REPH or CPIX? 62.3% of Recro Pharma shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 14.2% of Recro Pharma shares are owned by company insiders. Comparatively, 43.3% of Cumberland Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is REPH or CPIX more profitable? Recro Pharma has a net margin of -15.15% compared to Cumberland Pharmaceuticals' net margin of -29.54%. Cumberland Pharmaceuticals' return on equity of -9.50% beat Recro Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Recro Pharma-15.15% -56.66% -11.14% Cumberland Pharmaceuticals -29.54%-9.50%-3.19% Which has preferable valuation & earnings, REPH or CPIX? Cumberland Pharmaceuticals has lower revenue, but higher earnings than Recro Pharma. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Recro Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRecro Pharma$75.36M0.00-$11.37M-$0.31N/ACumberland Pharmaceuticals$39.55M0.38-$6.28M-$0.77-1.38 Does the media refer more to REPH or CPIX? In the previous week, Cumberland Pharmaceuticals had 1 more articles in the media than Recro Pharma. MarketBeat recorded 1 mentions for Cumberland Pharmaceuticals and 0 mentions for Recro Pharma. Recro Pharma's average media sentiment score of 0.00 equaled Cumberland Pharmaceuticals'average media sentiment score. Company Overall Sentiment Recro Pharma Neutral Cumberland Pharmaceuticals Neutral Which has more risk & volatility, REPH or CPIX? Recro Pharma has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. SummaryRecro Pharma beats Cumberland Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Ad DTILet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now Get Cumberland Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPIX vs. The Competition Export to ExcelMetricCumberland PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.88M$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-1.3811.10105.1417.83Price / Sales0.38362.031,233.15158.41Price / Cash1.6152.5940.4136.29Price / Book0.6110.377.096.50Net Income-$6.28M$153.60M$119.65M$226.22M7 Day Performance-7.02%4.60%2.25%4.03%1 Month Performance-14.52%-6.29%-2.33%4.92%1 Year Performance-38.01%33.41%33.98%29.30% Cumberland Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPIXCumberland Pharmaceuticals0.4591 of 5 stars$1.06-1.9%N/A-38.7%$14.88M$39.55M-1.3880High Trading VolumeREPHRecro PharmaN/AN/AN/AN/A$117.93M$75.36M-6.74185LLYEli Lilly and Company4.9919 of 5 stars$749.50-0.1%$1,007.94+34.5%+25.7%$711.52B$34.12B81.0243,000Analyst RevisionJNJJohnson & Johnson4.9567 of 5 stars$154.79-0.5%$175.94+13.7%+2.9%$372.68B$85.16B22.62131,900Positive NewsABBVAbbVie4.9685 of 5 stars$178.14+3.7%$203.50+14.2%+27.9%$314.80B$54.32B61.3850,000Analyst ForecastAnalyst RevisionPositive NewsMRKMerck & Co., Inc.4.9978 of 5 stars$101.27+1.4%$130.86+29.2%-2.5%$256.18B$63.17B21.2072,000Dividend IncreasePositive NewsPFEPfizer5 of 5 stars$25.71+2.3%$32.92+28.1%-15.5%$145.70B$58.50B34.5888,000Analyst DowngradeOptions VolumeAnalyst RevisionBMYBristol-Myers Squibb4.7982 of 5 stars$58.62+0.7%$54.07-7.8%+19.1%$118.89B$45.01B-16.2234,100Analyst RevisionPositive NewsZTSZoetis4.8738 of 5 stars$176.96+0.1%$221.44+25.1%-1.3%$79.84B$8.54B33.2214,100Positive NewsRPRXRoyalty Pharma4.779 of 5 stars$26.44+0.2%$41.67+57.6%-2.8%$15.58B$2.36B13.6980JAZZJazz Pharmaceuticals4.8871 of 5 stars$126.42+1.1%$175.33+38.7%+4.1%$7.64B$3.83B17.622,800Analyst ForecastNews CoverageGap Up Related Companies and Tools Related Companies REPH Alternatives LLY Alternatives JNJ Alternatives ABBV Alternatives MRK Alternatives PFE Alternatives BMY Alternatives ZTS Alternatives RPRX Alternatives JAZZ Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CPIX) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cumberland Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cumberland Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
